Serina Therapeutics Inc (SER)

Form EFFECT - Notice of Effectiveness

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-3 - Registration statement under Securities Act of 1933

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

 Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Form PRE 14A - Other preliminary proxy statements

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma –...

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE...

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans